newsfilter
← Latest News
GlobeNewswire·

Long-term Survival Data from Longeveron's ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic